Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Obesity or Overweight
Interventions: RO7795081, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 36
States / cities: Anniston, Alabama • Lake Forest, California • Rancho Cucamonga, California + 31 more

Conditions: Vitrectomy
Interventions: Dexamethasone Phosphate Ophthalmic Solution; Drug
Lead sponsor: Eyegate Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ovarian Cancer Recurrent
Interventions: Ombrabulin (AVE8062), Placebo, Paclitaxel, Carboplatin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 5
States / cities: Burbank, California • New Haven, Connecticut • Fort Meyers, Florida + 2 more

Conditions: Chronic Lower Limb Pain
Interventions: AXIUM Neurostimulator System, Control Spinal Cord Stimulation Device; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 22
States / cities: Phoenix, Arizona • Aptos, California • Carlsbad, California + 19 more

Conditions: Bowel Preparation
Interventions: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution, Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 917 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 12
States / cities: Huntsville, Alabama • Anaheim, California • Chula Vista, California + 9 more

Conditions: COVID-19
Interventions: AZD7442, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 5,197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 60
States / cities: Birmingham, Alabama • Tempe, Arizona • Little Rock, Arkansas + 53 more

Conditions: Sjögren Syndrome
Interventions: Remibrutinib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute-On-Chronic Liver Failure, Ascites
Interventions: VS-01 on top of SOC, SOC (Control Group); Drug · Other
Lead sponsor: Genfit; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 13
States / cities: Sacramento, California • Washington D.C., District of Columbia • Tampa, Florida + 9 more

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: FCR001; Biological
Lead sponsor: Talaris Therapeutics Inc.; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Age-Related Macular Degeneration (AMD)
Interventions: pegaptanib sodium (Macugen); Drug
Lead sponsor: Eyetech Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Abilene, Texas

Conditions: Renal Impairment
Interventions: Sulthiame; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Altamonte Springs, Florida • Miami Lakes, Florida

Conditions: Bladder, Neurogenic
Interventions: tamsulosin hydrochloride, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 7
States / cities: Los Angeles, California • Tampa, Florida • St Louis, Missouri + 4 more

Conditions: Degeneration of Lumbar Intervertebral Disc
Interventions: chronOS Strip; Device
Lead sponsor: Synthes USA HQ, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 13
States / cities: Birmingham, Alabama • Hartford, Connecticut • Brandon, Florida + 9 more

Conditions: Lymphoblastic Leukemia, Acute, Childhood
Interventions: Clofarabine incorporated into a 5-drug regimen; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 1 Year to 30 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 6
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 3 more

Conditions: Pancreatic Carcinoma, Tumors That Express CA 19-9
Interventions: MVT-1075, MVT-5873; Drug
Lead sponsor: BioNTech Research & Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Scottsdale, Arizona • New York, New York

Conditions: Multiple System Atrophy, Parkinsons Disease
Interventions: Sural Nerve Graft to the Substantia Nigra, Sham surgery; Procedure
Lead sponsor: Craig van Horne, MD, PhD; Other
Eligibility: 40 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: methadone hydrochloride, morphine sulfate, oxycodone hydrochloride; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Spartanburg, South Carolina • Houston, Texas

Conditions: Secondary Hypogonadism
Interventions: Androxal; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 68 Years · Male only
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 18
States / cities: Birmingham, Alabama • Huntsville, Alabama • Carmichael, California + 14 more

Conditions: Renal Impairment
Interventions: tolebrutinib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 3
States / cities: Miami, Florida • Saint Paul, Minnesota • Knoxville, Tennessee

Conditions: Alpha-Synucleinopathy, Parkinson's Disease, Dementia With Lewy Bodies, Multisystem Atrophy
Interventions: [18F]MNI-1216; Drug
Lead sponsor: Invicro; Other
Eligibility: 21 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Magnetic Resonance Imaging
Interventions: Gadoxetate disodium (Eovist/Primovist, BAY86-4873); Drug
Lead sponsor: Bayer; Industry
Eligibility: Up to 2 Months
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 6 more

Conditions: Non-Hodgkin's Lymphoma
Interventions: autologous immunoglobulin idiotype-KLH conjugate vaccine; Drug
Lead sponsor: Genitope Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Indianapolis, Indiana + 6 more

Conditions: Oral Mucositis
Interventions: AG013, Placebo; Biological · Other
Lead sponsor: Oragenics, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 27
States / cities: Farmington, Connecticut • Newark, Delaware • Orlando, Florida + 24 more

Conditions: Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Interventions: SAR443820, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Search by objective public record fields.

A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

PK Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Undergoing Vitrectomy

Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel

A Safety and Effectiveness Trial of Spinal Cord Stimulation of the Dorsal Root Ganglion for Chronic Lower Limb Pain

A Study Comparing the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution With PREPOPIK® for Colon Cleansing in Preparation for Colonoscopy

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.

A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome

Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®

A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis

A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD

Study of Sulthiame (S-054502) in Participants With Renal Impairment and Matched Healthy Controls

Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder

Prospective, Multi-Center Clinical Outcomes Study Evaluating the chronOS Strip Combined With Bone Marrow Aspirate

A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)

Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy

Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism

Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.

Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain

Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day

Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants